Abstract: The invention relates to a method for determining the total clotting activity of a blood or plasma sample, characterized in that a highly specific, reversible thrombin inhibitor is added to a blood or plasma sample in a defined amount, the clotting of the blood or plasma sample is induced and, after a defined period of time, the consumed amount of the added thrombin inhibitor is determined in a per se known manner, as well as to a kit for obtaining information about the state of coagulation of a blood sample.

Abstract: The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps. The body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary. To the non-turbid body liquid thus obtained are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfg1, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfg1, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfg1, resp., and as an option prothrombin. The thus obtained solution or mixture, resp., is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time.

Abstract: An interactive system is provided with at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). The interactive system is suitable for presenting and eliminating substances in liquids.

Abstract: The invention relates to measuring of the adhesion of platelets ex vivo. In this method, monodisperse polymer particles are added to blood, and the number of platelets in the blood are measured before and after shaking of the sample. The level of adhesion of the platelets is determined by comparing the number of platelets prior to shaking with the number of platelets after shaking. Methods of establishing an adhesion index and diagnosis of a patient are also provided.

Abstract: The present invention relates to novel covalent oligo and polyalkylene glycol conjugates with synthetic inhibitors of trypsin-type serine proteases, in particular inhibitors of the hemocoagulation protease thrombin, synthetic intermediates stages required in their production and their use for producing active ingredients for the treatment or prophylaxis of thrombotic complications.

Abstract: The invention relates to a method for determining the total clotting activity of a blood or plasma sample, characterized in that a highly specific, not irreversible thrombin inhibitor is added to a blood or plasma sample in a defined amount, the clotting of the blood or plasma sample is induced and, after a defined period of time, the consumed amount of the added thrombin inhibitor is determined in a per se known manner, as well as to a kit for obtaining information about the state of coagulation of a blood sample.

Abstract: The invention relates to the use of increased-molecular-weight hirudin for the manufacture of an anticoagulant for extracorporeal renal replacement therapy which does not induce an autoimmune disease and which does not cross react with autoimmune antibodies. In particular, the use according to the invention does not induce type II thrombocytopenia (HIT II), and no cross reactivity occurs with antibodies to platelet-factor-4-heparin complexes.

Abstract: The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps. The body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary. To the non-turbid body liquid thus obtained are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., and as an option prothrombin. The thus obtained solution or mixture, resp., is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time.

Abstract: The invention relates to a blood-compatible surface comprising a polymer surface and a plurality of conjugates made of linkers and active agents immobilized thereon. The polymer surface contains similar or different structural units that carry carbonyl groups. The linkers contain a structural element that is able to form a hydrogen bridge bond. A polyorganosiloxane acting as the active agent is linked to the linkers.

Abstract: The present invention relates to an adsorption system for the removal of viruses and viral components, in particular hepatitis C viruses, from physiological fluids, in particular whole blood or blood plasma, by means of extracorporeal adsorption processes, as well as to an adsorber material for use in the adsorption system of the present invention.

Abstract: The invention relates to a method for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid. It comprises the following steps. The body liquid is taken from a living body, and the body liquid is subjected to a separation from the turbid matter, if necessary. To the non-turbid body liquid thus obtained are added a coagulation-inhibiting substance not interfering in the transformation prothrombin/active meizothrombin or Mtdesfgl, resp., a chromogenic or fluorogenic substrate not dissociable by active meizothrombin or Mtdesfgl, resp., and a substance dissociating prothrombin into meizothrombin or Mtdesfgl, resp., and as an optional prothrobmin. The thus obtained solution or mixture, resp., is subjected to a wavelength-selective light absorption or light emission measurement as a function of the time.

Abstract: An interactive system is provided with at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). The interactive system is suitable for presenting and eliminating substances in liquids.

Abstract: The present invention relates to an interactive system comprising at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). That interactive system is suitable for presenting and eliminating substances in liquids.

Abstract: The present invention relates to novel covalent oligo and polyalkylene glycol conjugates with synthetic inhibitors of trypsin-type serine proteases, in particular inhibitors of the hemocoagulation protease thrombin, synthetic intermediates stages required in their production and their use for producing active ingredients for the treatment or prophylaxis of thrombotic complications.

Abstract: The present invention relates to a process for separating substances, which are bonded to a polymer surface via a linker, by adding a polar organic solvent.

Abstract: The invention relates to the use of increased-molecular-weight hirudin for the manufacture of an anticoagulant for extracorporeal renal replacement therapy which does not induce an autoimmune disease and which does not cross react with autoimmune antibodies. In particular, the use according to the invention does not induce type II thrombocytopenia (HIT II), and no cross reactivity occurs with antibodies to platelet-factor-4-heparin complexes.

Abstract: The invention relates to the use of monodisperse polymer particles of human albumin, fibrin, fibrinogen or polyphenylmethacrylate for quantitative measuring of the adhesion of platelets in vitro.

Abstract: The invention relates to a process for the diagnosis of illnesses, pathologic states as well as physiological measurement units, which is based on the immobilization of recognition structures by means of a specific linker at specific functional polymer surfaces.

Abstract: The present invention relates to an interactive system comprising at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). That interactive system is suitable for presenting and eliminating substances in liquids.

Abstract: This invention relates to the use of an inhibitor of an activatable metabolic enzyme, which inhibitor is bound to a high molecular weight carrier, as a molecular marker for determining the activation of this enzyme for the diagnosis of the enzyme. The invention relates in particular to the use of a thrombin inhibitor, which is bound to a high molecular weight carrier, as a molecular marker for determining clotting activation in clotting diagnosis and therapy monitoring. The invention preferably relates to the use of dextran-hirudin or PEG-coupled hirudin as a molecular marker for clotting diagnosis and therapy monitoring.